Nexpoint Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nexpoint Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,000	Closed	-$417K	–	178
2021 Q2	$417K	Hold	5,000	–	–	0.09%	105
2021 Q1	$378K	Hold	5,000	–	–	0.1%	103
2020 Q4	$438K	Hold	5,000	–	–	0.14%	114
2020 Q3	$380K	Sell	5,000 -10,000	-67%	-$1.01M	0.09%	124
2020 Q2	$1.85M	Buy	15,000 +9,000	+150%	+$894K	0.42%	47
2020 Q1	$507K	Hold	6,000	–	–	0.1%	127
2019 Q4	$507K	Hold	6,000	–	–	0.04%	199
2019 Q3	$404K	Buy	+6,000	New	+$462K	0.03%	267

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nexpoint Asset Management's BMRN Position: Q3 2021 in Review

Nexpoint Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 5,000 shares — an estimated $417K sold.

Nexpoint Asset Management first reported a position in BMRN in Q3 2019 and held it in 8 quarters. The position peaked at $1.85M in Q2 2020. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

Nexpoint Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Nexpoint Asset Management sold 5,000 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $417K.
Nexpoint Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2019 and held it in 8 quarters.
Nexpoint Asset Management's BioMarin Pharmaceuticals position peaked at $1.85M in Q2 2020.
511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Nexpoint Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.